1-7 of 7
Atsushi Shinagawa, MD PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with IDH 1/2 Mutations

Daniel A. Pollyea, Courtney D. Dinardo, MDMSc, Martha L. Arellano, MD, Arnaud Pigneux, MD PhD, Walter Fiedler, MD, Marina Konopleva, MD PhD, David A Rizzieri, MD, B. Douglas Smith, MD, Atsushi Shinagawa, MD PhD, Roberto M. Lemoli, Monique Dail, PhD, Yinghui Duan, PhD, Brenda J. Chyla, Jalaja Potluri, MD, Jean A Ridgeway, DNP, NP-C, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 5–7.
https://doi.org/10.1182/blood-2020-134736
Published: 2020
Journal Articles

Efficacy and Safety of Once-Weekly Cyclophosphamide-Bortezomib-Dexamethasone (CBD) Regimen As Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma. -a Phase 2 Multicenter Trial-

Daisuke Kudo, MD, Takuya Komeno, MD MPH, PhD, Chikashi Yoshida, MD PhD, Ikuyo Ota Tsutsumi, MD, Kazuteru Ohashi, MD PhD, Kazuhiko Kakihana, MD PhD, Takeshi Kobayashi, MD, Noriko Doki, MD PhD, Yuho Najima, MD, Aiko Igarashi, MD, Mitsuo Hori, MD PhD, Yasushi Okoshi, MD PhD, Takayuki Fujio, MD, Atsushi Shinagawa, MD PhD, Masahide Yamamoto, MD PhD, Hina Takano, MD PhD, Takashi Kumagai, MD PhD, Koh Yamamoto, MD PhD, Shigeo Toyota, MD PhD, Yuichi Nakamura, MD PhD, Hiroshi Kojima, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2160.
https://doi.org/10.1182/blood-2018-99-113788
Published: 2018
Journal Articles

Optimal Treatment Strategy with Nilotinib for Patients with Newly Diagnosed Chronic Myelogenous Leukemia in the Chronic Phase Based on Early Achievement of Deep Molecular Response (MR 4.5 ) : First Report from N-Road, a Phase II Study in Japan

Kaichi Nishiwaki, MD PhD, Kei-Ji Sugimoto, MD PhD, Shigehisa Tamaki, MD PhD, Junichi Hisatake, MD PhD, Hisayuki Yokoyama, MD PhD, Tadahiko Igarashi, MD PhD, Atsushi Shinagawa, MD PhD, Takeaki Sugawara, MD PhD, Satoru Hara, MD PhD, Kazuhisa Fujikawa, MD PhD, Seiichi Shimizu, MD PhD, Yujiri Toshiaki, MD PhD, Arinobu Tojo, MD PhD, Hisashi Wakita, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1925.
https://doi.org/10.1182/blood.V128.22.1925.1925
Published: 2016
Journal Articles

Phase 2 Study of Lenalidomide in Combination with Low-Dose Dexamethasone in Japanese Transplantation-Ineligible Newly-Diagnosed Multiple Myeloma Patients

Takaaki Chou, Atsushi Shinagawa, MD PhD, Toshiki Uchida, MD, Masafumi Taniwaki, MD PhD, Hirokazu Hirata, MD PhD, Kenichi Ishizawa, MD PhD, Kosei Matsue, MD PhD, Yoshiaki Ogawa, MD, Takayuki Shimizu, MD PhD, Maki Otsuka, MD, Morio Matsumoto, MD, Shinsuke Iida, Yasuhito Terui, MD PhD, Itaru Matsumura, Takashi Ikeda, MD PhD, Naoki Takezako, MD PhD, Yumi Ogaki, MD, Shuichi Midorikawa, MD, Vanessa Houck, Annette Ervin-Haynes, Kenshi Suzuki, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3452.
https://doi.org/10.1182/blood.V124.21.3452.3452
Published: 2014
Journal Articles

Multicenter Phase II Clinical Trial of Nilotinib for Patients with Imatinib-Resistant or Intolerant CML From the East Japan CML Study Group (EJCML) Trial: Evaluation of Molecular Responses by the BCR-ABL1 Mutational Status and Plasma Trough Concentration of Nilotinib

Naoto Takahashi, MD, PhD, Masatomo Miura, PhD, Jun Kuroki, MD, PhD, Kinuko Mitani, MD, PhD, Atsushi Kitabayashi, MD, PhD, Osamu Sasaki, MD, PhD, Hideo Kimura, MD, PhD, Kiyotoshi Imai, MD, PhD, Norifumi Tsukamoto, MD, PhD, Hideyoshi Noji, MD, PhD, Takeshi Kondo, MD, PhD, Akihisa Kuwayama, MD, PhD, Mutsuhito Motegi, MD, PhD, Yuichi Kato, MD, PhD, Kaoru Takahashi, MD, PhD, Masayuki Mita, MD, PhD, Hajime Saito, MD, PhD, Chikashi Yoshida, MD, PhD, Yoshihiro Torimoto, MD, PhD, Tomofumi Kimura, MD, PhD, Yuji Wano, MD, PhD, Jun Nomura, MD, PhD, Satoshi Yamamoto, MD, PhD, Ko Mayama, MD, PhD, Riko Honma, MD, PhD, Tomohiro Sugawara, MD, PhD, Shinji Sato, MD, PhD, Atsushi Shinagawa, MD, PhD, Akihiko Chubachi, MD, PhD, Hideo Harigae, MD, PhD, Kenichi Sawada, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 1360.
https://doi.org/10.1182/blood.V120.21.1360.1360
Published: 2012
Journal Articles

Relative Increase of Lymphocytes As Early As 1 Month After Initiation of Dasatinib Is a Reliable Predictor for Achieving Complete Molecular Response At 12 Months in Chronic Phase CML Patients Treated with Dasatinib

Eri Matsuki, MD, PhD, Takashi Kumagai, MD, Koiti Inokuchi, MD, PhD, Kazuteru Ohashi, M.D., Atsushi Shinagawa, MD, PhD, Jin Takeuchi, MD, PhD, Chikashi Yoshida, MD, PhD, Shinichiro Okamoto, MD, PhD, Hisashi Wakita, MD, Yasuji Kozai, MD, Yukari Shirasugi, MD, Shin Fujisawa, MD, Osamu Iwase, MD, Shingo Yano, MD, Kaichi Nishiwaki, MD, Koji Oba, MD, Junichi Sakamoto, MD, Hisashi Sakamaki, MD
Journal: Blood
Blood (2012) 120 (21): 691.
https://doi.org/10.1182/blood.V120.21.691.691
Published: 2012
Journal Articles

Relevance of the Daily Dose of Imatinib Mesylate (IM) Rather Than Its Trough Plasma Concentration for Achieving Deep Molecular Response in Patients with Chronic Myeloid Leukemia.

Chikashi Yoshida, MD, PhD, Takuya Komeno, MD, MPH, PhD, Mitsuo Hori, MD, PhD, Tomofumi Kimura, MD, PhD, Masami Fujii, MD, PhD, Yasushi Okoshi, MD, PhD, Kazumi Suzukawa, MD, PhD, Shigeru Chiba, MD, PhD, Yuichi Hasegawa, MD, PhD, Harumi Yamamoto Mukai, MD, PhD, Takayoshi Ito, MD, PhD, Seiichi Shimizu, MD, PhD, Masaharu Kamoshita, MD, PhD, Daisuke Kudo, MD, Atsushi Shinagawa, MD, PhD, Norio Chikatsu, MD, PhD, Yuriko Monma, MD, Norimichi Watanabe, MD, PhD, Hiroshi Kojima, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 1112.
https://doi.org/10.1182/blood.V114.22.1112.1112
Published: 2009